Structurally designed shRNAs
    73.
    发明授权

    公开(公告)号:US10329562B2

    公开(公告)日:2019-06-25

    申请号:US15451016

    申请日:2017-03-06

    Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Agog because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

    VARIETAL COUNTING OF NUCLEIC ACIDS FOR OBTAINING GENOMIC COPY NUMBER INFORMATION

    公开(公告)号:US20190153535A1

    公开(公告)日:2019-05-23

    申请号:US16269818

    申请日:2019-02-07

    Abstract: A method for obtaining from genomic material genomic copy number information unaffected by amplification distortion, comprising obtaining segments of the genomic material, tagging the segments with substantially unique tags to generate tagged nucleic acid molecules, such that each tagged nucleic acid molecule comprises one segment of the genomic material and a tag, subjecting the tagged nucleic acid molecules to polymerase chain reaction (PCR) amplification, generating tag associated sequence reads by sequencing the product of the PCR reaction, assigning each tagged nucleic acid molecule to a location on a genome associated with the genomic material by mapping the subsequence of each tag associated sequence read corresponding to a segment of the genomic material to a location on the genome, and counting the number of tagged nucleic acid molecules assigned to the same location on the genome having a different tag, thereby obtaining genomic copy number information unaffected by amplification distortion.

    Methods and compositions for treating Alzheimer's disease
    77.
    发明授权
    Methods and compositions for treating Alzheimer's disease 有权
    治疗阿尔茨海默病的方法和组合物

    公开(公告)号:US09271987B2

    公开(公告)日:2016-03-01

    申请号:US13949403

    申请日:2013-07-24

    CPC classification number: A61K31/5377 A61K31/517

    Abstract: This disclosure relates to methods and compositions useful for treating Alzheimer's disease. In particular, the disclosure relates to pharmaceutical compositions containing an EGFR-inhibitory compound suitable for administration to treat Alzheimer's disease, as well as to related therapeutic methods. In addition, this disclosure relates to screening methods for identifying compounds useful for treating Alzheimer's disease based on the ability to inhibit the activity of EGFR.

    Abstract translation: 本公开涉及可用于治疗阿尔茨海默氏病的方法和组合物。 特别地,本公开涉及含有适合于治疗阿尔茨海默病的EGFR抑制性化合物的药物组合物以及相关的治疗方法。 此外,本公开涉及基于抑制EGFR活性的能力鉴定用于治疗阿尔茨海默氏病的化合物的筛选方法。

    AUGMENTED COGNITIVE TRAINING
    79.
    发明申请
    AUGMENTED COGNITIVE TRAINING 审中-公开
    加强认知训练

    公开(公告)号:US20150141441A1

    公开(公告)日:2015-05-21

    申请号:US14603787

    申请日:2015-01-23

    CPC classification number: A61K38/1709 A61K31/00 A61K48/00 A61N1/30 G09B19/00

    Abstract: The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents.

    Abstract translation: 本发明提供了与中枢神经系统疾病或病症相关的认知缺陷的治疗方法,增强认知功能的方法和用于反复刺激神经元活动或神经元活动模式的方法,例如潜在于特定神经元电路 )。 所述方法包括组合认知训练方案和CREB通路增强剂的总体给药。

    DRUG SCREENING METHOD AND USES THEREOF
    80.
    发明申请
    DRUG SCREENING METHOD AND USES THEREOF 审中-公开
    药物筛选方法及其用途

    公开(公告)号:US20140297199A1

    公开(公告)日:2014-10-02

    申请号:US14356975

    申请日:2012-11-09

    Inventor: Pavel Osten

    CPC classification number: G01N33/5008 G01N33/5014 G01N33/5041 G01N2333/82

    Abstract: Described herein are methods of screening drugs in a non-human animal using high resolution technology leading to generation of pharmacomaps. Further described herein are methods of predicting the therapeutic benefit and/or toxicity of drug candidate compounds. In specific embodiments, provided herein are methods of predicting the clinical effects of a test drug based on comparison of the pharmacomap of the test drug to the pharmacomap of one or more reference drugs with known clinical outcomes.

    Abstract translation: 本文描述的是使用导致产生药物代谢的高分辨率技术在非人动物中筛选药物的方法。 本文进一步描述了预测药物候选化合物的治疗益处和/或毒性的方法。 在具体实施方案中,本文提供了基于将测试药物的药物试剂与具有已知临床结果的一种或多种参考药物的药物组合物进行比较来预测测试药物的临床效果的方法。

Patent Agency Ranking